Influenza A virus infection often causes large outbreaks of febrile illness among infants and young children and can precede community outbreaks of influenza in adults (7, 9, 26) . During influenza A epidemics, up to three-quarters of the patients seen by pediatricians for outpatient care may have influenza A virus infections (26) . Influenza A virus infections in children are often complicated by otitis media (9, 26, 27) . A vaccine effective in preventing illness and decreasing dissemination of infection among infants and young children would reduce the attack rate of influenza in the general population and may reduce associated illnesses, such as otitis media, in the age group at greatest risk for middle ear infection (9, 10, 12, 16, 21) .
Cold-adapted, live, attenuated reassortant vaccines have been derived from the influenza A/Ann Arbor/6/60 virus master strain that donates six RNA segments coding for internal proteins and wild-type influenza viruses that contribute RNA segments encoding for hemagglutinin and neuraminidase (the 6/2 reassortant) (5, (13) (14) (15) . Studies with adults and children indicate that these intranasally administered attenuated vaccines are safe and protect against experimental challenge (1-4, 8, 17, 18, 25) . However, crossreacting antibodies to influenza virus from previous naturally occurring infections may inhibit replication of live attenuated vaccines in the respiratory tract. These live attenuated vaccines have not been evaluated in children less than 1 year of age. However, this is the age group in whom the intranasal attenuated vaccines may prove to be most useful. Administration of these vaccines to infants and young children would avoid the problem of inhibition of replication of vaccine virus by preexisting antibodies from previous influenza virus infections (1, 2, 18, 25) . Furthermore, influenza virus causes significant morbidity in infants (26) . The purpose of this study was to evaluate the safety and antigenicity of CR-59 influenza A/Korea (H3N2) virus vaccine in infants and to determine whether maternal antibody against related influenza A virus strains would inhibit the infectivity of the vaccine. We also determined the amount of vaccine virus required to infect 50% of infants following intranasal vaccination.
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MATERIALS AND METHODS
Clinical studies. Families with infants 5 to 15 months of age were recruited from pediatric practices in the community. The infants were examined by a pediatrician. After screening tests of complete blood count, liver function tests, urinalysis, tuberculosis skin test, and serum antibody to influenza A virus, the mothers were asked to volunteer their healthy infants to receive cold-adapted H3N2 vaccine or to serve as unvaccinated controls. Infants whose mothers were pregnant were excluded from the study.
The infants were examined for signs of respiratory illness 3 days before vaccination, and nose and throat swabs were taken for isolation of viruses. Twenty-four healthy children were inoculated intranasally (0. 25 (19) .
Genetic stability studies on vaccine virus recovered from infants. Preparation, maintenance, and infection of primary chick kidney (PCK) cells were done by established procedures (13, 14) . The plaque assays for evaluation of the phenotypes were performed in PCK cells by infecting confluent monolayers in 25-cm2 plastic flasks with 1.0 ml of virus diluted in Eagle minimum essential medium. Virus was adsorbed for 1 h at room temperature with continuous, gentle rocking, after which the virus inoculum was aspirated off and 5 ml of overlay medium consisting of 0.8% purified agar (BBL Microbiology Systems, Cockeysville, Md.) in modified 199 medium was added. After incubation for 48 h at 33 and 39°C or for 5 days at 25°C, the monolayers were stained by adding 4 ml of 0.8% agar to the modified medium 199 containing 0.01% neutral red. Plaques were read on days 5, 6, and 7 for the cultures incubated at 33 and 39°C and on days 6 to 12 for the cultures incubated at 25°C.
Gene constellations of the vaccine virus and isolates of virus that were recovered from respiratory secretions were determined as described previously (5, 20) . Briefly, the virus was grown for 2 days in PCK cells with [3H]uridine to label the viral RNA. The harvest was purified and lysed, and the viral RNA was electrophoresed on two 3.0% polyacrylamide-0.6% agarose mixed gels (230 V, 18 h, 30 and 37°C). The viral RNA was also run on a 1.5% agarose gel (60 V, 18 h, 37°C). Both types of gels were run in 1x TBE (0.09 M Trizma base, 0.09 M boric acid, 1 mM disodium EDTA) with 0.1% sodium dodecyl sulfate. After the run, the mixed gels were soaked on 0.75% M sodium salicylate containing 0.1% hexadecyltrimethylammonium bromide for 45 min. The agarose gel was soaked in En3Hance (Dupont, NEN Research Products, Boston, Mass.) for 45 min and then in H20 for 30 min. Both types of gels were then dried and exposed to X-ray film at -70°C for 24 to 48 h.
Viruses recovered from infants were also examined for the attenuation phenotype by evaluation in ferrets. Infection of ferrets was done by a procedure published earlier (15) . Ferrets were inoculated intranasally and examined for coryza, rhinitis, and fever twice a day for the duration of the experiment. Nasopharyngeal swabs were taken daily, and on days 3 and 8 ferrets were sacrificed and 20% suspensions of turbinate and lung tissues were made in nutrient broth. The viruses in these samples were titrated in embryonated eggs.
RESULTS
Infection of children with CR-59. All four infants who received 106.2 TCID50 of vaccine virus shed vaccine virus in (Fig. 2) . ELISA antibody to influenza A/Korea virus hemagglutinin was present in all cord sera. The mean ELISA titer was 3,881 at birth (Fig. 2) . By the time of vaccination at 4 to 13 months of age, a significant loss of maternal antibody had occurred; antibody titers were 10-fold lower, with a mean ELISA titer of 341. At 1 month postvaccination, vaccinees who were infected by vaccine virus had a mean ELISA titer of 1,000. The mean antibody titer continued to increase beyond 1 month postvaccination. At 6 months and 1 year after vaccination, the mean ELISA titers were 6,309 and 8,483, respectively, among infected vaccinees (Fig. 2) .
Clinical response to CR-59. infants had otitis media, but only one infant had lower respiratory tract disease and otitis media concurrently. Herpes simplex virus was cultured from the upper airway of one of these infants, and a nonpolio enterovirus was cultured from respiratory secretions of the other infant. Genetic stability of vaccine virus removed from infants. Twenty-one isolates from the trials were examined for genetic stability as determined by retention of the cold adaptation, temperature sensitivity, and attenuation phenotypes and the 6/2 gene profile (Table 3) . Two isolates from nasal swabs (clones 16592 and 16620) were intermediate in temperature sensitivity upon amplification in embryonated eggs. The infectivity titer at 39°C when compared with that at 33°C showed a 102 to 103 reduction when compared with the rest of the isolates, for which no observable infectivity (>103 reduction) at 39°C was recorded. However, upon further analysis in ferrets, these two isolates retained the attenuation phenotype and were cold adapted and temperature sensitive (Table 3) . DISCUSSION The infectivity of this vaccine was directly proportional to the vaccine dose given; the infective dose for 50% of the infants was 104 6 TCIDO. This is similar to the 50% infective doses of the other cold-adapted influenza A virus vaccines that have been evaluated in children 1 to 5 years old but 100-fold lower than that observed for adults (1, 8, 17, 24) . The cold-adapted influenza A virus vaccines which have been evaluated previously in seronegative children include influenza A/California 10/78 (HlNi) virus. The dose of cold-recombinant influenza A/California virus necessary to infect 50% of children was approximately 103-5 TCID50 (14) .
In adults screened for low levels of nasal wash antibody or low antibody levels in serum, the amount of cold-adapted vaccine virus required to infect 50% of the volunteers was between 105-5 and 106-5 TCID50 with influenza A/Washington/897/80 (H3N2) virus and between 105 8 and 106 8 TCID50
for influenza A California 10/78 (HlNi) virus (3, 17, 22, 24) .
In this study, adverse effects were not related to vaccine dose. Otitis media was the most frequent significant adverse effect observed among the vaccinees and controls in this study and is of particular concern among infants. The most common complication of upper respiratory tract infection in children is otitis media, and the peak incidence occurs in the 6-to 12-month age group (9, 16, 26) . As many as 30% of infants have had at least one episode of otitis media by 1 year of age, and by 2 years of age over 60% of children have experienced one or more middle ear infections (10, 12, 21) .
Children who experience an initial attack of otitis media in year 1 of life are at increased risk of recurrence (16) .
Influenza A has been associated with otitis media, and control of this epidemic illness may reduce the incidence of otitis media among young children (9, 26, 27) . The possible association of vaccine virus with otitis media was a concern.
In this study, only two of the episodes of otitis media occurred in infants infected with the vaccine virus. (9) were able to identify the etiology of viral respiratory infection in only 39% of initial episodes of otitis media. Other investigators have not detected a significant increase in otitis media among children vaccinated with these live intranasally administered vaccines (1, 2, 24) . However, other studies involved older children, and the risk of otitis media among younger vaccinees must be determined. Antibody concentrations achieved in serum after administration of CR-59 vaccine were, for the most part, in the range that correlated with protection against clinical influenza illness, and the antibody titers remained stable for a year (1, 2, 11 ). There was a delay in achieving maximum antibody titers among the children who were infected by vaccine virus. This further increase in antibody titers between 1 and 6 months postvaccination was not likely due to intercurrent influenza A virus infection. Although intercurrent natural infection with influenza A virus may have boosted the antibody titers, this is unlikely. Infants who were vaccinated with CR-59 but did not become infected with vaccine virus had antibody titers that remained low for the 1 year of follow-up; the geometric mean ELISA titers of vaccinated infants who were not infected by CR-59 at 1 month, 6 months, and 1 year postvaccination were 158, 54, and 69, respectively.
Even though we vaccinated some infants who were less than 6 months old, the maternal antibody level was low by the vaccination date and these low maternal antibody levels did not seem to influence the infants' susceptibilities to vaccine virus. This is in contrast to findings after parenteral immunization against measles virus (6) . Further studies with this and other cold-adapted influenza virus vaccines should be conducted in infants, since this population is at risk for significant disease and is susceptible to infection with these live attenuated vaccines.
